Balloon implant for prostate cancer passes Long-Term safety check
NCT ID NCT05354440
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 80 prostate cancer patients who previously received a BioProtect balloon implant during radiation therapy. Researchers are checking for long-term side effects in the bladder and bowel, and how patients' quality of life holds up over time. The goal is to make sure the implant remains safe years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BioProtect balloon implant system
What this could lead to
If successful, this study could confirm that the BioProtect balloon implant is a safe long-term option to reduce side effects during prostate cancer radiation therapy.
What could go wrong
This is a small, observational follow-up study with only 80 participants, so results may not apply to all patients. It does not test a new treatment, only monitors past outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assuta Ashdod medical center
Ashdod, Israel
-
Cuf Porto institution
Porto, Portugal
-
Institute of Maria Skłodowska - Curie
Warsaw, Poland
-
Maastricht radiation oncology
Maastricht, Netherlands
-
Rabin Medical Center
Petah Tikva, Israel
-
St Luke's Radiation Oncology
Dublin, Ireland